REGENXBIO to Present at the 44th Annual J.P. Morgan Healthcare Conference

About this update from Regenxbio Inc.

ROCKVILLE, Md. , Dec. 18, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will present at the 44th Annual J.P. Morgan Healthcare Conference . Presentation DetailsDate and Time: Wednesday, January 14, 2026 at 10:30 a.m. PT Location: Westin St. Francis , San Francisco, CA A live webcast of the presentation can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com . An archived replay of the webcast will be available for approximately 30 days following the presentation. ABOUT REGENXBIO Inc. REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; clemidsogene lanparvovec (RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA®. REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people. For more information, please visit WWW.REGENXBIO.COM . Contacts: Dana Cormack Corporate Communications [email protected] Investors: George E. MacDougall Investor Relations [email protected] View original content to download multimedia: https://www.prnewswire.com/news-releases/regenxbio-to-present-at-the-44th-annual-jp-morgan-healthcare-conference-302645444.html SOURCE REGENXBIO Inc.

View stock analysis, news, and events for Regenxbio Inc.